CardioDx, Inc. Nixes IPO, Cites Unfavorable Market Conditions

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CardioDx postpones its initial public offering, citing 'unfavorable market conditions.' California molecular diagnostics company CardioDx spiked its initial public offering, citing "unfavorable market conditions," according to news reports. The 5.8-million-share offering by Palo Alto-based CardioDx was slated to raise $92 million at a share price of $14-$16 apiece. The IPO, originally scheduled for yesterday, would have seen CardioDx shares trade under the "CDX" symbol.

Help employers find you! Check out all the jobs and post your resume.

Back to news